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Abstract
Purpose To investigate the efficacy of metformin (M) plus chemotherapy versus chemotherapy alone in metastatic breast 
cancer (MBC).
Methods Non-diabetic women with HER2-negative MBC were randomized to receive non-pegylated liposomal doxorubicin 
(NPLD) 60 mg/m2 + cyclophosphamide (C) 600 mg/m2 × 8 cycles Q21 days plus M 2000 mg/day (arm A) versus NPLD/C 
(arm B). The primary endpoint was progression-free survival (PFS).
Results One-hundred-twenty-two patients were evaluable for PFS. At a median follow-up of 39.6 months (interquartile 
range [IQR] 24.6–50.7 months), 112 PFS events and 71 deaths have been registered. Median PFS was 9.4 months (95% CI 
7.8–10.4) in arm A and 9.9 (95% CI 7.4–11.5) in arm B (P = 0.651). In patients with HOMA index < 2.5, median PFS was 
10.4 months (95% CI 9.6–11.7) versus 8.5 (95% CI 5.8–9.7) in those with HOMA index ≥ 2.5 (P = 0.034). Grade 3/4 neu-
tropenia was the most common toxicity, occurring in 54.4% of arm A patients and 72.3% of the arm B group (P = 0.019). 
M induced diarrhea (G2) was observed in 8.8% of patients in Arm A. The effect of M was similar in patients with HOMA 
index < 2.5 and ≥ 2.5, for PFS and OS.
Conclusions The MYME trial failed to provide evidence in support of an anticancer activity of M in combination with first 
line CT in MBC. A significantly shorter PFS was observed in insulin-resistant patients (HOMA ≥ 2.5). Noteworthy, M had 
a significant effect on CT induced severe neutropenia. Further development of M in combination with CT in the setting of 
MBC is not warranted.
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Introduction
There is increasing evidence that the insulin pathway is 
involved in the development and prognosis of a variety of 
human neoplasms, including breast cancer (BC) [1]. This 
association is biologically plausible as hyperinsulinemia 
induces proliferative tissue abnormalities due to the strong 
anabolic effect of insulin, resulting in the enhancement of 
DNA synthesis and cell proliferation [2]. This effect may also 
be attributable to the cross-activation of the insulin-like growth 
factor (IGF) receptor family. Insulin-like growth factors (IGFs) 
are endocrine mediators of growth hormones that also act in 
a paracrine and autocrine manner to regulate cell growth, dif-
ferentiation, apoptosis, and transformation in numerous tissues 
including the breast [3]. The downstream pathway of the insu-
lin/IGF system is well defined: IGF-I and insulin activate the 
tyrosine kinase growth receptor pathway, i.e., insulin, IGF-I, 
and hybrid IGF-I/insulin receptors, all of which are overex-
pressed in breast cancer cells. Activation of these receptors 
results in the upregulation of the insulin receptor-substrate-2 
(IRS2), leading to the downstream activation of the MAPKi-
nase and PI3K-Akt pathways [4]. It has also been shown that 
stimulation of the insulin receptor by insulin or IGFs enhances 
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cancer cell proliferation. These findings suggest that the insu-
lin/IGF pathway may be involved in tumor development and 
progression, and might thus represent a novel therapeutic tar-
get [5]. Furthermore, in patients with BC, higher circulating 
insulin levels have been found to be associated with adverse 
outcome, while IGF1 levels do not appear to have such an 
impact [6, 7] .
Within this context, it has been suggested that metformin 
(M), the most widely prescribed anti-diabetic drug for the 
treatment of hyperglycaemia and hyperinsulinemia [8], may 
improve prognosis in BC patients [9]. M is an oral biguanide 
that inhibits hepatic gluconeogenesis and sensitizes insulin 
action at the peripheral level. It is also widely prescribed for 
the treatment of type 2 diabetes [10] because of its good toler-
ability, and is approved by FDA for the prevention of diabetes 
in healthy at-risk subjects [11]. Pre-clinical data have shown 
that the key mechanism of action of M is the through activa-
tion of the AMPK pathway, resulting in a regulation of cellular 
energy homeostasis and an improvement in insulin sensitivity 
[12]. Epidemiological studies on diabetic patients indicate an 
association between the use of M and reduced BC incidence 
and mortality with respect to other antidiabetic drugs, espe-
cially in overweight/insulin-resistant women [13]. It can there-
fore be hypothesized that the potential antineoplastic effect 
of M in vivo is related either to its direct effect on cancer cell 
metabolism or to its indirect effect through the reduction of 
systemic insulin levels and hyperglycaemia, especially in 
insulin-resistant patients.
There are little clinical data on the effect of M as an anti-
cancer agent. In a large observational study of BC patients 
treated with pre-operative chemotherapy, the proportion of 
M-treated diabetic patients achieving a pathological com-
plete response was significantly higher than that of diabetic 
patients treated with other antidiabetic drugs and of non-
diabetic BC patients [14]. More recently, in a window of 
opportunity, double-blind, randomized study in early BC 
patients, the administration of M for 4 weeks before surgery 
did not impact tumor proliferation, compared to baseline lev-
els, in the overall patient population. However, a significant 
effect of M on Ki-67 was seen in insulin-resistant patients 
[15]. A large adjuvant trial on non-diabetic women with 
early BC comparing M with matching placebo in terms of 
disease-free survival (DFS) is currently ongoing [16, 17]. 
The present clinical trial evaluated the anticancer effect of 
M used in association with first-line chemotherapy in MBC.
Methods
Study design and participants
The MYME (Myocet® - Metformin) trial was a phase II, 
open-label, multicenter, randomized clinical trial aimed at 
assessing whether the addition of M to first-line chemo-
therapy in HER2-negative MBC is associated with a clini-
cal effect, thus warranting further research. The study was 
approved by the Ethics Committee of each participating 
center and was conducted in accordance with the Declara-
tion of Helsinki, Good Clinical Practice norms and local 
and national regulatory requirements. Written informed 
consent was obtained from all patients before study entry. 
The study is registered in Clinicaltrials.gov (NCT01885013) 
and in European Clinical Trials Database (EudraCT No. 
2009-014662-26).
Women were eligible if they met the following criteria: 
stage IV histologically or cytologically confirmed MBC, 
HER2-negative disease (determined by immunohistochem-
istry [IHC] or fluorescence in situ hybridization [FISH]); 
non endocrine-responsive disease (negative hormonal sta-
tus or failure of endocrine therapy in metastatic disease); 
measurable and/or non-measurable disease according to 
RECIST Criteria (Version 1.1) [18]; availability of HOMA 
index calculated according to Matthews’ formula [19]; 
prior endocrine therapy was allowed in the adjuvant and/or 
metastatic setting; prior chemotherapy was allowed in the 
adjuvant setting providing patients had completed it at least 
12 months before study entry; adjuvant anthracyclines were 
allowed if prior cumulative dose did not exceed 360 mg/
m2 for epirubicin and 280 mg/m2 for doxorubicin; adjuvant 
taxanes; age 18 to 75 years; Eastern Cooperative Oncology 
Group performance status (ECOG PS) ≤ 2; normal organ and 
bone marrow functions; and left ventricular ejection fraction 
(LVEF) > 50%. Patients with known diabetes (type 1 or 2) 
were excluded.
Randomization
Patients were randomly assigned (1:1) with a centralized 
procedure to one of two treatment groups: first-line chemo-
therapy alone or chemotherapy plus M. Randomization was 
performed using a computer-generated list and permuted 
blocks within strata. Randomization was stratified by center 
and HOMA index (< 2.5 vs ≥ 2.5). Investigators and patients 
were not masked to treatment assignment.
Treatment and procedures
Eligible patients were allocated to arm A (non pegylated 
liposomal doxorubicin (NPLD) 60 mg/m2 intravenously 
(i.v.) plus cyclophosphamide (C) 600 mg/m2 i.v plus M 
1000 mg twice daily) or arm B (NPLD 60 mg/m2 i.v. plus 
C 600 mg/m2 i.v.). Chemotherapy cycles were administered 
every 21 days for a maximum of 8 cycles. M was admin-
istered until disease progression. Staging procedures were 
performed at baseline a maximum of 28 days before ran-
domization and consisted in contrast-enhanced chest and 
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abdominopelvic CT scan. Other tests for tumor assessment 
were performed as clinically indicated. Disease status was 
monitored every 2 cycles (8 weeks) with the same radiologi-
cal exams used at baseline.
Anthropometric evaluation and biochemical and hemato-
logical laboratory tests were performed at baseline (within 
14 days before randomization), before each treatment cycle 
and every 3 months after the end of treatment. Anthropo-
metric evaluation included assessment of height and weight 
for body mass index (BMI) calculation and the waist-to-hip 
circumference ratio (WHR) determined by measuring the 
waist circumference at the narrowest part of the torso and 
the hip circumference in a horizontal plane at the level of 
the maximal extension of the buttocks.
After an overnight fast (> 8 h), blood samples were col-
lected to measure glycaemia, lipidaemia, serum free fatty 
acid levels, triglycerides, total cholesterol, high and low den-
sity lipoprotein, hormones (insulin, C-peptide, norepineph-
rine, cortisol), inflammatory markers, including those inde-
pendently associated with insulin resistance or cancer, i.e., 
C-reactive protein, erythrocyte sedimentation rate, tumor 
necrosis factor alpha, interleukin-6. A HOMA index ≥ 2.5 
was chosen as the cut-off value for insulin resistance based 
on the results from an Italian-based population study [20].
Outcomes
Progression-free survival (PFS) was calculated from the date 
of randomization to the date of disease progression, death 
from any cause, or loss to follow-up, whichever came first. 
PFS of patients with no events who were lost to follow-up 
were censored on the date of the last tumor evaluation. Simi-
larly, overall survival (OS) was computed from the day of 
randomization to the date of death from any cause or loss to 
follow-up. Response and progression were evaluated by the 
Response Evaluation Criteria in Solid Tumors (RECIST ver-
sion 1.1). Adverse events were recorded and graded accord-
ing to the National Cancer Institute (NCI-CTC) common 
toxicity criteria version 3.0 (CTC 3.0) [21].
Statistical analysis
The primary objective of the study was to compare the effi-
cacy of the combination NPLD plus C plus M with NPLD 
plus C in HER2-negative MBC in terms of PFS. The study 
size was estimated using a two-sided log rank test with 
alfa = 10% and power = 80%. To detect a 4-month increase 
in the median time to progression, from 6 months in the 
control arm (arm B) to 10 months in the experimental arm 
(arm A), corresponding to an hazard ratio (HR) of 0.6, 98 
events had to be observed. To this aim, the recruitment of 
112 patients was planned over a period of 24 months with a 
further follow-up of 12 months.
The primary analysis was performed on the intention-
to-treat (ITT) population, defined as the population of 
randomized patients who received at least one dose of 
the assigned study treatment. The safety population was 
considered as all the patients in the ITT population. The 
analysis of ORR was only performed in patients with 
measurable disease.
Continuous variables were presented as median (inter-
quartile range - IQR) and qualitative variables were pre-
sented as absolute or relative frequencies. Median follow-
up was measured from random treatment assignment to the 
date of last follow-up or death for patients alive at the time 
of cut-off for analysis. Time-to-event data (PFS, OS) were 
described using the Kaplan–Meier curves and compared 
with the log-rank test. Ninety-five percent confidence 
intervals (95% CI) were calculated by non-parametric 
methods. Estimated HRs and their 95% CI were calculated 
using univariate and multivariate Cox proportional hazard 
models. The ORR was calculated with an exact 95% CI 
using standard methods based on binomial distribution. 
Evaluation of toxicity was assessed with Cochran-Armit-
age test for trend.
As planned in the original protocol, the prognostic and 
predictive role of insulin sensitivity was evaluated by com-
paring PFS in patients with a HOMA index ≥ 2.5 versus 
< 2.5, and by introducing the HOMA index as a binary 
covariate in a Cox model, with PFS as the dependent vari-
able and treatment and HOMA index as covariates. The 
differential effect of M on PFS was evaluated by testing 
the interaction between treatment arm and HOMA index.
A multivariate model was fitted to further explore the 
therapeutic role of M in terms of PFS. One-hundred and 
twenty-two patients were included in multivariate analyses 
of PFS and the following covariates were fitted in a multi-
variate model: age, arm, estrogen receptor status, previous 
adjuvant chemotherapy, and HOMA index. The differential 
effect of M in strata defined by these factors was explored 
in a standard subgroup analysis by testing the interaction 
between treatment assignment and each of these factors.
Results of subgroup analyses were graphically sum-
marized using a forest plot. The significance of all HRs 
was evaluated by the log-Likelihood ratio test. No interim 
efficacy analysis was planned and only the safety of the 
experimental treatment was monitored throughout the 
study.
P-values were based on two-sided testing and results 
were deemed to be significant if P < 0.05. As an explora-
tory analysis, the Fisher exact test was used to evaluate 
modification in insulin sensitivity status. Statistical analy-
ses were carried out using STATA/MP 15.0 for Windows 
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(Stata Corp LP, USA). No correction for multiple testing 
was applied.
Results
Between April 7th 2010 and May 29th 2015, 126 patients 
were randomized from 16 centers. Four (3%) patients (two 
from each arm) were excluded from the analysis (two with-
drew consent, one did not meet eligibility criteria because 
of prior chemotherapy for MBC, and one was lost to follow 
up immediately after randomization). The trial profile is rep-
resented in Fig. 1. Patient and disease characteristics were 
well balanced between the two arms (Table 1). Median age 
at randomization was 60 years (IQR 51–66). ECOG PS was 
0 in 77% of patients. One hundred and six patients (87%) had 
ER-positive BC, 89 patients (73%) had measurable disease 
and 78 patients (64%) had visceral involvement. Prior adju-
vant anthracyclines were administered in 56 (46%) patients.
After a median follow-up of 39.6 months (IQR 
24.6–50.7), 112 (92%) PFS events had been observed, 52 
(92%) in arm A and 60 (92%) in arm B. Median PFS was 
9.4 (95% CI 7.8–10.4) and 9.9 (95% CI 7.4–11.5) months 
in arms A and B, respectively (HR 1.09, 95% CI 0.75–1.58, 
P = 0.653). PFS curves are shown in Fig. 2. Seventy-one 
patients had died, 30 (53%) in arm A and 41 (63%) in arm 
B. Median OS was 34.4 (95% CI 19.3–37.2) and 26.8 (95% 
CI 19.4–37.9) months, respectively (HR 0.81, 95% CI 
0.50–1.30, P = 0.382) (Fig. 3). Eighty-nine patients with 
measurable disease were evaluable for response. ORR was 
48% (95% CI 32.0% − 63.5%) in arm A and 49% (95% CI 
34.1% − 63.9%) in arm B (P = 0.901). In the subgroup analy-
sis (Fig. 4), no significant variation in the effect of M in PFS 
was observed (all P values for interaction > 0.1).
As expected, neutropenia was the most frequently 
reported toxicity, with grade (G) 3/4 events occurring in 54% 
of arm A patients and 72% of arm B patients (P = 0.019). 
Febrile neutropenia occurred in one patient in arm A com-
pared to six patients in arm B (P = 0.076). Other toxicities 
related to M administration included G2 diarrhea observed 
in 8% of patients in arm A and 0% in arm B. There was no 
clinical evidence of cardiotoxicity (New York Heart Asso-
ciation Functional Classification G3/4) in either arm. The 
most frequent adverse events observed during treatment are 
reported in Table 2.
Overall, 57 of the 122 evaluable patients were insu-
lin-resistant, as measured by HOMA index ≥ 2.5. When 
patients with HOMA index ≥ 2.5 were compared with those 
with HOMA index < 2.5, a significant difference in PFS 
was observed (HR = 1.51, 95% CI 1.03–2.20, P = 0.034) 
(Fig. 5). Median OS was 30.8 (95%CI 19.4–41.4) and 
27.2 months (95%CI 19.3–37.0) in patients with HOMA 
index < 2.5 and ≥ 2.5 respectively and, no association 
between HOMA index and OS was observed (HR = 0.97, 
95% CI 0.61–1.55, P = 0.900). The effect of M was simi-
lar in patients with HOMA < 2.5 and in those HOMA 
index ≥ 2.5 both for PFS and for OS (p value for interaction 
0.997 and 0.942, respectively). Multivariate PFS analysis 
revealed that older age (> 50 years) (HR = 1.57, 95% CI 
0.99–2.49, P = 0.046), adjuvant chemotherapy (HR = 1.62, 
Fig. 1  CONSORT diagram
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95% CI 1.08–2.44, P = 0.016), presence of insulin resist-
ance as defined by HOMA index ≥ 2.5 (HR = 1.51, 95% CI 
1.02–2.23, P = 0.037) and negative estrogen receptor status 
(HR = 2.56, 95% CI 1.45–4.55, P = 0.003), were associated 
with an increased risk of disease progression.
In an exploratory analysis, the proportion of patients 
showing a modification in insulin sensitivity during treat-
ment was evaluated in a subset of 100 patients with at least 
one assessment of the HOMA index after randomization. 
At baseline there were 23 patients in arm A and 25 in arm 
B with HOMA index > 2.5. Conversion to insulin sensitiv-
ity was observed in 11 (48%) in arm A and in 4 (16%) in 
arm B (P = 0.029). Conversely, 4/22 (18%) patients in arm 
A and 7/30 (23%) in arm B became insulin-resistant after 
randomization (P = 0.741).
Discussion
This is the first study to evaluate the impact of the addi-
tion of M to first-line CT in MBC. Its results indicate that 
the administration of M did not show any advantage in 
terms of PFS compared to CT alone. Similarly, no effect 
was observed in terms of OS. Furthermore, no benefit in 
PFS was observed in insulin-resistant patients classified 
by HOMA index ≥ 2.5. This result was unexpected since, 
Table 1  Baseline patient 
characteristics
Data are median (IQR) or number of patients (%)
IQR interquartile range, ER estrogen receptor, PgR progesterone receptor, ECOG Eastern Cooperative 
Oncology Group
Arm A: NPLD/C/M 
(N = 57)
No. (%)






Median age, years (IQR range) 57 (50–68) 61 (54–66) 60 (51–66)
 > 50 years 42 (74%) 51 (79%) 93 (76%)
Menopausal status
 Post-menopausal 47 (83%) 53 (82%) 100 (82%)
 ER-positive 50 (88%) 56 (86%) 106 (87%)
 PgR-positive 44 (77%) 43 (66%) 87 (71%)
ECOG performance status
 0 46 (81%) 48 (74%) 94 (77%)
 1 9 (16%) 17 (26%) 26 (21%)
 2 2 (4%) 0 (0%) 2 (2%)
Treatment
 Prior adjuvant chemotherapy 38 (67%) 35 (54%) 73 (60%)
 Anthracyclines 30 (53%) 26 (40%) 56 (46%)
 Prior adjuvant endocrine therapy 39 (68%) 36 (55%) 75 (62%)
 Prior endocrine therapy for MBC 17 (30%) 27 (42%) 44 (36%)
Dominant metastatic site
 Bone only 9 (16%) 10 (15%) 19 (16%)
 Viscera 37 (65%) 41 (63%) 78 (64%)
 Soft tissue 11 (19%) 14 (22%) 25 (21%)
No. of metastatic sites
 1 24 (42%) 15 (23%) 39 (32%)
 2 14 (25%) 26 (40%) 40 (33%)
 > 2 19 (33%) 24 (37%) 43 (35%)
Measurable disease 42 (74%) 47 (72%) 89 (73%)
Body mass index (BMI)
 < 25 26 (46%) 25 (39%) 51 (42%)
 ≥ 25 and < 30 17 (30%) 33 (51%) 50 (41%)
 > 30 14 (25%) 7 (11%) 21 (17%)
HOMA index
 < 2.5 28 (49%) 37 (57%) 65 (53%)
 ≥ 2.5 29 (51%) 28 (43%) 57 (47%)
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at the time the study was planned, increasing evidence 
was suggesting that M could retain an anticancer activ-
ity either through a direct effect on cancer cell metabo-
lism by AMPK pathway activation or through an indirect 
effect associated with the host metabolism modulation, 
especially in insulin-resistant patients.
Of note, this result was consistent with recent findings 
by our group showing no effect of M on tumor prolifera-
tion, measured by Ki-67, in patients with early BC who were 
candidates for primary surgery [15]. Indeed, a significant 
interaction between M and HOMA index was detected, espe-
cially in luminal B tumors, supporting the hypothesis of an 
Fig. 2  Kaplan–Meier curves 
for A progression-free survival 
by arm
Fig. 3  Kaplan–Meier curves for 
overall survival by arm
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indirect effect of M in insulin-resistant patients [15]. The 
present study on advanced BC patients fails to support this 
hypothesis, suggesting that, in the presence of aggressive 
tumor load, the potential effect of M on host metabolism 
is less important in modulating response to chemotherapy.
A strong prognostic effect of insulin sensitivity was 
observed in our study, with insulin-resistant patients 
(HOMA index ≥ 2.5) showing a significantly lower PFS 
compared to non insulin-resistant women, irrespective of 
the use of M. This association has never been reported 
before. Several reports suggest a worse prognosis among 
obese women with ER-positive early BC [22, 23], but the 
association has not been consistently observed and is not 
present in early BC patients with rapidly proliferating or 
triple-negative disease [24–26]. Furthermore, no evidence 
of an adverse prognostic effect of higher BMI was observed 
in MBC patients treated with chemotherapy [27]. These 
findings support the hypothesis that obesity, per se, is not 
a prognostic factor in BC, whereas evidence linking high 
plasma insulin levels with adverse BC prognosis suggests 
that insulin sensitivity may play a key role [6]. In our study, 
almost one in two M-treated patients with baseline HOMA 
Fig. 4  Subgroup analysis of progression free survival
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index ≥ 2.5 became insulin-sensitive compared to one in 
six in arm B, confirming the strong activity of M on host 
metabolism, as recently shown in early BC [17]. However, 
this did not translate into a beneficial effect on PFS or OS 
in the present study.
An intriguing finding of our study is the significantly 
decreased incidence of severe neutropenia (P = 0.019) and 
febrile neutropenia (P = 0.076) in the M arm. Of note, the 
incidence of severe neutropenia in the control arm (72%) 
was in line with that previously reported for the same chem-
otherapy regimen. The protective effect of M on 131I-induced 
neutropoenia has also been previously reported in diabetic 
patients with differentiated thyroid cancer [28]. Thus, con-
firmation of our finding is needed to evaluate the poten-
tial protective properties of M on bone marrow toxicity 
induced by neutropenic treatments such as chemotherapy 
and radiotherapy.
Conclusion
In conclusion, the addition of M to first-line chemotherapy 
in MBC did not provide a meaningful clinical benefit in 
terms of PFS or OS, but decreased the incidence of severe 
Table 2  Adverse events in 
patients receiving at least one 
cycle of treatment







G0–G1 G2 G3–G4 G0–G1 G2 G3–G4
Absolute neutrophil count 23 (40%) 3 (5%) 31 (54%) 13 (20%) 5 (8%) 47 (72%) 0.019
Febrile neutropenia 56 (98%) 0 (0%) 1 (2%) 59 (91%) 0 (0%) 6 (9%) 0.076
Anemia 47 (82%) 9 (16%) 1 (2%) 52 (80%) 11 (17%) 2 (3%) 0.654
Thrombocytopenia 51 (89%) 3 (5%) 3 (5%) 60 (92%) 2 (3%) 3 (5%) 0.681
Nausea 38 (67%) 17 (30%) 2 (4%) 51 (78%) 12 (19%) 2 (3%) 0.200
Vomiting 43 (75%) 12 (21%) 2 (4%) 60 (92%) 4 (6%) 1 (2%) 0.019
Fatigue 30 (54%) 22 (39%) 4 (7%) 54 (83%) 7 (11%) 4 (6%) 0.005
Diarrhea 52 (91%) 5 (9%) 0 (0%) 65 (100%) 0 (0%) 0 (0%) 0.014
Mucositis 51 (89%) 5 (9%) 1 (2%) 62 (95%) 3 (5%) 0 (0%) 0.081
Infection 56 (98%) 1 (2%) 0 (0%) 62 (95%) 3 (5%) 0 (0%) 0.376
Alopecia 55 (96%) 1 (2%) 1 (2%) 62 (95%) 2 (3%) 1 (2%) 0.867
Fig. 5  Kaplan–Meier curves 
for progression free survival by 
HOMA index
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neutropenia. Insulin resistance was a strong adverse prog-
nostic factor in MBC and adequate lifestyle interventions 
should be therefore recommended for patients in both early 
and advanced disease settings. Randomized trials [17] are 
ongoing to define whether M-induced changes in insulin 
sensitivity and host metabolism in early BC are associated 
with an important clinical benefit.
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